Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial

Blood

Volumn 101, Issue 6, 2003, Pages 2426-2433

  Van Rhenen, Dick ^a   Gulliksson, Hans ^b   Cazenave, Jean Pierre ^b   Pamphilon, Derwood ^b   Ljungman, Per ^b   Klüter, Harald ^b   Vermeij, Hans ^b   Kappers Klunne, Mies ^b   De Greef, Georgine ^b   Laforet, Michel ^b   Lioure, Bruno ^b   Davis, Kathryn ^b   Marblie, Stephane ^b   Mayaudon, Veronique ^b   Flament, Jocelyne ^b   Conlan, Maureen ^b   Lin, Lily ^b   Metzel, Peyton ^b   Buchholz, Don ^b   Corash, Laurence ^b  

^a CERUS CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET BUFFY COAT; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOCHEMISTRY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SAFETY; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ULTRAVIOLET RADIATION;

EID: 0037443546     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0932     Document Type: Article

References (31)

1. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med. 1996;334:1685-1690.
2. Ling AE, Robbins KE, Brown TM, et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA. 2000;284:238-240.
3. Schuttler GC, Caspari G, Jursch CA, Willems WR, Gerlich WH, Schaefer S. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet. 2000;355:41-42.
4. McDonald CP, Hartley S, Orchard K, et al. Fatal Clostridium perfrinngens sepsis from a pooled platelet transfusion. Transfusion Med. 1998;8:19-22.
5. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423-435.
6. Alfonso R, Lin C, Dupuis K, et al. Inactivation of viruses with preservation of coagulation function in fresh frozen plasma. Blood. 1996;88(suppl 1):526a.
7. Lin L, Corten L, Murthy KK, Corash L, Alter HJ. Photochemical inactivation of hepatitis B (HBV) and hepatitis C (HCV) virus in human platelet concentrates as assessed by a chimpanzee infectivity model. Blood. 1998;92(suppl 1):502a.
8. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffycoat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sanguinis. 2000;78:209-216.
9. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by psoralen plus UVA. Blood. 1998;91:2180-2188.
10. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93:3140-3147.
11. van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sanguinis. 2000;79:206-214.
12. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;2:109-117.
13. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of a stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet. 1991;338:1223.
14. TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861-1869.
15. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
16. Sweeney JD, Kouttab NM, Penn CL, McHugh KE, Nelson EJ, Oblon DJ. A comparison of prestorage WBC-reduced whole-blood-derived platelets and bedside-filtered whole-blood-derived platelets in autologous progenitor cell transplant. Transfusion. 2000;40:794-800.
17. Klumpp TR, Herman JH, Gaughan JP, et al. Clinical consequences of alterations in platelet transfusion dose: a prospective randomized, double-blind trial. Transfusion. 1999;39:674-681.
18. van Rhenen DJ, Vermeii J, Kappers-Klunne MC, Payrat JM. Evaluation of a new citrate-acetateNaCl platelet additive solution for the storage of white cell reduced platelet concentrates obtained from half strength CPD pooled buffy coats. Transfusion. 1995;35:50-53.
19. Murphy S, Heaton WA, Rebulla P. Platelet production in the Old World - and the New. Transfusion. 1996;36:751-754.
20. Bertolini F, Rebulla P, Riccardi D, Cortellaro M, Ranzi ML, Sirchia G. Evaluation of platelet concentrates prepared from buffy coats and stored in glucose-free crystalloid medium. Transfusion. 1989;29:605-609.
21. Eriksson L, Kristensen J, Olsson J. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coats and apheresis. Vox Sanguinis. 1996;70:69-75.
22. McCullough J, Vesole D, Benjamin RJ, et al. Pathogen inactivated platefets (pft) using Helinx technology (INTERCEPT plt) are hemostatically effective in thrombocytopenic patients (tcp pts): the SPRINT trial. Blood. 2001;98(suppl 1):450a.
23. Leach MF, AuBuchon JP. Effect of storage time on clinical efficacy of single-donor platelet units. Transfusion. 1993;33:661-664.
24. Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J. Factors influencing 20-hour increments after platelet transfusion. Transfusion. 1991;31:392-396.
25. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing efficacy of pooled platelet transfusions. Blood. 1988;71:383-387.
26. Ishida A, Handa M, Wakui M, Okamoto S, Kamakura M, Ikeda Y. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation-a prospective analysis. Transfusion. 1998;38:839-847.
27. Enright H, Gernsheimer T, Woodson R, et al. Factors influencing the response to platelet transfusion. Blood. 1997;90(suppl 1):268a.
28. Davis KB, Slichter SJ, Corash L. Corrected count increments and platelet recoveries as measures of post-transfusion platelet response: problems and a solution. Transfusion. 1999;39:586-592.
29. Norol F, Bierling P, Roudot-Thoraval F, et al. Platelet transfusion: a dose-response study. Blood. 1998;92:1448-1453.
30. Vermeij J, Mayaudon V, Flament J, et al. The INTERCEPT platelet system for pathogen inactivation with an integral processing set demonstrated improved process control for production of platelet concentrates. Vox Sanguinis. 2002;83(suppl 2):110.
31. Ciaravino V. Preclinical safety of a nucleic acidtargeted helinx compound: a clinical perspective. Semin Hematol. 2001;38(suppl 11):12-19.